- Home
- GBR vs QLGN Comparison
GBR vs QLGN Comparison
Compare GBR & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBR
- QLGN
- Stock Information
- Founded
- GBR 1978
- QLGN 1996
- Country
- GBR United States
- QLGN United States
- Employees
- GBR N/A
- QLGN N/A
- Industry
- GBR Oil & Gas Production
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- GBR Energy
- QLGN Health Care
- Exchange
- GBR Nasdaq
- QLGN Nasdaq
- Market Cap
- GBR 5.2M
- QLGN 5.8M
- IPO Year
- GBR N/A
- QLGN N/A
- Fundamental
- Price
- GBR $0.84
- QLGN $2.82
- Analyst Decision
- GBR
- QLGN
- Analyst Count
- GBR 0
- QLGN 0
- Target Price
- GBR N/A
- QLGN N/A
- AVG Volume (30 Days)
- GBR 37.7K
- QLGN 3.5M
- Earning Date
- GBR 11-12-2025
- QLGN 11-14-2025
- Dividend Yield
- GBR N/A
- QLGN N/A
- EPS Growth
- GBR N/A
- QLGN N/A
- EPS
- GBR N/A
- QLGN N/A
- Revenue
- GBR $153,000.00
- QLGN N/A
- Revenue This Year
- GBR N/A
- QLGN N/A
- Revenue Next Year
- GBR N/A
- QLGN N/A
- P/E Ratio
- GBR N/A
- QLGN N/A
- Revenue Growth
- GBR 4.08
- QLGN N/A
- 52 Week Low
- GBR $0.67
- QLGN $1.61
- 52 Week High
- GBR $1.78
- QLGN $8.81
- Technical
- Relative Strength Index (RSI)
- GBR 39.93
- QLGN 43.97
- Support Level
- GBR $0.86
- QLGN $2.36
- Resistance Level
- GBR $0.87
- QLGN $2.85
- Average True Range (ATR)
- GBR 0.06
- QLGN 0.28
- MACD
- GBR -0.00
- QLGN 0.00
- Stochastic Oscillator
- GBR 5.77
- QLGN 44.51
About GBR New Concept Energy Inc
New Concept Energy Inc is a United States-based company engaged in Real Estate Operations. It intends to continue to operate and or sell its West Virginia property. It provides advisory and management services for an independent West Virginia oil and gas company. The Company seeks to establish or acquire new business operations. It operates in one segment, which is real estate rental.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.